ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0549

High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study

Suzan Attar1, Siraj Walli2, Yasser Bawazir3, Mohammad Mustafa4, Ayah Boudal5, Faris alhejailli2, Ahmad Bamagoos2 and Omar Kanbr2, 1King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, 2KAU, Jeddah, Saudi Arabia, 3King Abdulaziz University, Jeddah, Saudi Arabia, 4Jeddah University, Jeddah, Saudi Arabia, 5King Abdullah Medical Complex, Jeddah, Saudi Arabia

Meeting: ACR Convergence 2025

Keywords: Psoriatic arthritis, sleep, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Background: Obstructive sleep apnea (OSA) is increasingly recognized in patients with psoriatic arthritis (PsA), yet few studies have used polysomnography (PSG)—the gold-standard diagnostic method. This study bridges this gap by employing PSG to definitively characterize OSA prevalence and its relationship with PsA disease activity.Objective: To determine OSA prevalence in PsA using PSG and evaluate associations with disease activity.

Methods: This two-stage cross-sectional study included adult PsA patients. Stage 1: Participants were screened using the STOP-BANG questionnaire for OSA risk and the Epworth Sleepiness Scale (ESS) for daytime sleepiness. Disease activity was assessed using DAPSA and DAS28-CRP, and functional status by HAQ. Stage 2: All patients at high risk and a random 50% sample of low/intermediate-risk patients underwent overnight PSG. OSA was defined by apnea–hypopnea index (AHI) ≥5 events/hour and categorized as mild (5–14), moderate (15–29), or severe (≥

Results: Sixty-eight patients (69% female, mean age 46 years, mean BMI 29 kg/m²) were enrolled. Sleep-related symptoms were reported by 77% (snoring 53%, morning fatigue 68%). Mean disease activity scores: DAPSA 20±14, DAS28-CRP 2.8±1.0, HAQ 0.6±0.8. Based on STOP-BANG, 19% were high-risk, 35% intermediate, and 46% low-risk. PSG was performed in 42 patients (all high-risk and selected low/intermediate-risk). OSA was confirmed in 50%: 14% mild, 19% moderate, 17% severe. The estimated prevalence of moderate-to-severe OSA in the full cohort was 36%. Higher STOP-BANG scores (OR 2.35, p = 0.016) and older age (OR 1.13 per year, p = 0.007) were significant predictors of OSA. No significant correlation was found between OSA and PsA disease activity or comorbidities.

Conclusion: OSA is highly prevalent among PsA patients, with 50% testing positive by PSG. Despite this burden, OSA showed no association with disease activity. Routine screening and early sleep specialist referral for at-risk PsA patients may improve recognition and management. Further longitudinal, multicenter studies are needed to explore the role of psoriasis severity and treatment effects on OSA risk.

Supporting image 1


Disclosures: S. Attar: AbbVie/Abbott, 1, 5, 6, Amgen, 1, 5, 6, AstraZeneca, 1, 5, 6, Bristol-Myers Squibb(BMS), 1, 5, 6, Eli Lilly, 1, 5, 6, Gilead, 1, 5, 6, GlaxoSmithKlein(GSK), 1, 5, 6, Hikma, 1, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 5, 6, Organon, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 1, 5, 6, Sandoz, 1, 5, 6, Sanofi, 1, 5, 6, Takeda, 1, 5, 6; S. Walli: None; Y. Bawazir: None; M. Mustafa: None; A. Boudal: None; F. alhejailli: None; A. Bamagoos: None; O. Kanbr: None.

To cite this abstract in AMA style:

Attar S, Walli S, Bawazir Y, Mustafa M, Boudal A, alhejailli F, Bamagoos A, Kanbr O. High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/high-prevalence-of-obstructive-sleep-apnea-in-psoriatic-arthritis-a-polysomnography-based-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-prevalence-of-obstructive-sleep-apnea-in-psoriatic-arthritis-a-polysomnography-based-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology